FR0010259150
© Globe Newswire
19.03.2025
IPN
LISTED
EURONEXT
Ipsen announces issuance of €500 million inaugural Rated Public Bond
News Preview
Transaction follows Investment Grade ratings assignment from both S&P and Moody’s...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.03.2025
IPN
LISTED
EURONEXT
Ipsen appoints Olivia Brown as Executive Vice-President, Global Head of Neurotoxins
News Preview
PARIS, FRANCE, March 12th, 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-driven company, announced today the appointment of Olivia Brown as, EVP, Global Head of Neurotoxins, effective April 1st, 2025. She will serve on Ipsen’s Executive Leadership Team (ELT) and report directly to Chief Executive Officer David Loew. In this new...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.03.2025
IPN
LISTED
EURONEXT
Ipsen - February 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
News Preview
Monthly information relative to the total number of voting rights and shares composing the share capital...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
21.02.2025
IPN
LISTED
EURONEXT
Ipsen S.A. publishes its 2024 consolidated financial statements
News Preview
Ipsen S.A. - 2024 Consolidated Financial Statements...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
13.02.2025
IPN
LISTED
EURONEXT
Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025
News Preview
PARIS, FRANCE, 13 February 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the full year 2024....
Themefolio
Profiler
Peergroup
© Globe Newswire
06.02.2025
IPN
LISTED
EURONEXT
Ipsen - January 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
News Preview
Monthly information relative to the total number of voting rights and shares composing the share capital...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2025
IPN
LISTED
EURONEXT
Ipsen - Half year statement - 2024 12 31
News Preview
Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2025
IPN
LISTED
EURONEXT
Ipsen - December 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
News Preview
Monthly information relative to the total number of voting rights and shares composing the share capital...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2024
IPN
LISTED
EURONEXT
Ipsen - November 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
News Preview
Monthly information relative to the total number of voting rights and shares composing the share capital...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.12.2024
IPN
LISTED
EURONEXT
Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology
News Preview
PARIS, FRANCE; 03 December 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) and Biomunex Pharmaceuticals today announced an exclusive global licensing agreement for BMX-502. BMX-502 is a bispecific antibody that engages and activates a subset of cytotoxic T cells called Mucosal-Associated Invariant T cells (MAIT cells) and targets the GPC3 tumor antigen, t...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.11.2024
IPN
LISTED
EURONEXT
Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS
News Preview
PARIS, FRANCE, 18 November, 2024 Ipsen (Euronext: IPN; ADR: IPSEY) today announced data at the American Association for the Study of Liver Diseases (AASLD) assessing the long-term efficacy and safety of patients treated with Bylvay® from two Phase III open-label extension studies: late-breaking abstract (#5045) on PEDFIC 2 in Progressive Familial I...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.11.2024
IPN
LISTED
EURONEXT
Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus
News Preview
PARIS, FRANCE, 15 November 2024 Ipsen (Euronext: IPN; ADR: IPSEY) announced today late-breaking data for Iqirvo® (elafibranor 80 mg tablets) from an interim analysis of the ongoing open-label extension of the Phase III ELATIVE® study at the American Association for the Study of Liver Disease (AASLD) congress. The late-breaking presentations (Abstra...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
07.11.2024
IPN
LISTED
EURONEXT
Ipsen - October 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
News Preview
Monthly information relative to the total number of voting rights and shares composing the share capital...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.10.2024
IPN
LISTED
EURONEXT
Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance
News Preview
PARIS, FRANCE, 23 October 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its performance for the year to date and the third quarter of 2024....
Themefolio
Profiler
Peergroup
© Globe Newswire
14.10.2024
IPN
LISTED
EURONEXT
Ipsen receives its second Shingo Prize for operational excellence
News Preview
PARIS, FRANCE, 14 October 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that its Dublin, Ireland production site has received the Shingo Prize for operational excellence. This is Ipsen’s second Shingo Prize, with its site in Signes, France, receiving the first award in 2020....
Themefolio
Profiler
Peergroup
© Globe Newswire
09.10.2024
IPN
LISTED
EURONEXT
Ipsen - September 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
News Preview
Monthly information relative to the total number of voting rights and shares composing the share capital...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.09.2024
IPN
LISTED
EURONEXT
Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease
News Preview
...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.09.2024
IPN
LISTED
EURONEXT
Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis
News Preview
PARIS, FRANCE, 15 September 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today detailed final overall survival (OS) data from the Phase III CONTACT-02 trial investigating the combination of Cabometyx® (cabozantinib) and atezolizumab in metastatic castration-resistant prostate cancer (mCRPC). The trial investigated the combination regimen vers...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.09.2024
IPN
LISTED
EURONEXT
Ipsen - August 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
News Preview
Monthly information relative to the total number of voting rights and shares composing the share capital...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.08.2024
IPN
LISTED
EURONEXT
IPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 2024
News Preview
Aggregated presentation by day and by market...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.08.2024
IPN
LISTED
EURONEXT
IPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2024
News Preview
Aggregated presentation by day and by market...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.08.2024
IPN
LISTED
EURONEXT
Ipsen - July 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
News Preview
Monthly information relative to the total number of voting rights and shares composing the share capital...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.07.2024
IPN
LISTED
EURONEXT
IPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 2024
News Preview
Aggregated presentation by day and by market...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.07.2024
IPN
LISTED
EURONEXT
Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases
News Preview
Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.07.2024
IPN
LISTED
EURONEXT
Ipsen S.A. publishes its 2024 Half-Year Report (half-year ended 30 June 2024)
News Preview
Ipsen S.A. publishes its 2024 Half-Year Report (half-year ended 30 June 2024)...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.07.2024
IPN
LISTED
EURONEXT
Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance
News Preview
PARIS, FRANCE, 25 July 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the first half of 2024....
Themefolio
Profiler
Peergroup
© Globe Newswire
25.07.2024
IPN
LISTED
EURONEXT
Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor
News Preview
PARIS, FRANCE, and BRISBANE, CALIFORNIA U.S., 25 July 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) and Day One Biopharmaceuticals (Nasdaq: DAWN) (Day One), announced today a new global partnership outside the U.S. for tovorafenib, an oral, once-weekly, type II RAF inhibitor for pediatric low grade glioma (pLGG), the most common form of childhood brain...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.07.2024
IPN
LISTED
EURONEXT
IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2024
News Preview
Aggregated presentation by day and by market ...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.07.2024
IPN
LISTED
EURONEXT
IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2024
News Preview
Aggregated presentation by day and by market...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.07.2024
IPN
LISTED
EURONEXT
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential
News Preview
PARIS, FRANCE, 11 July 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) and Foreseen Biotechnology (Foreseen) today announced an exclusive global licensing agreement for FS001, an antibody-drug conjugate (ADC) with first-in-class potential. FS001 targets a novel tumor-associated antigen that is overexpressed in many solid tumors and plays a critical role i...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.07.2024
IPN
LISTED
EURONEXT
Ipsen - June 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
News Preview
Monthly information relative to the total number of voting rights and shares composing the share capital...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.07.2024
IPN
LISTED
EURONEXT
IPSEN - Buy-back programme - Art 5 of MAR - Week 27 - 2024
News Preview
Aggregated presentation by day and by market...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.07.2024
IPN
LISTED
EURONEXT
Half-year statement of IPSEN liquidity agreement - 2024 06 30
News Preview
Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.07.2024
IPN
LISTED
EURONEXT
IPSEN - Buy-back programme - Art 5 of MAR - Week 26 - 2024
News Preview
Aggregated presentation by day and by market...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.07.2024
IPN
LISTED
EURONEXT
Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial
News Preview
PARIS, FRANCE, 2 July 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today confirmation of an expanded collaboration and license agreement with Exelixis, Inc. for the development of Cabometyx® (cabozantinib) in advanced pancreatic neuroendocrine tumors (pNETs) and advanced extra-pancreatic neuroendocrine tumors (epNETs). The agreement is based...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.06.2024
IPN
LISTED
EURONEXT
IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2024
News Preview
Aggregated presentation by day and by market...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.06.2024
IPN
LISTED
EURONEXT
IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2024
News Preview
Aggregated presentation by day and by market...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.06.2024
IPN
LISTED
EURONEXT
IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2024
News Preview
Aggregated presentation by day and by market...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.06.2024
IPN
LISTED
EURONEXT
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
News Preview
...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.06.2024
IPN
LISTED
EURONEXT
Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo’s Tri-STAR platform
News Preview
PARIS, FRANCE, and CAMBRIDGE, MA, U.S., 07 June 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) and Marengo Therapeutics Inc, a clinical-stage biotech company, announced today the expansion of their ongoing oncology research partnership, to include TriSTAR, Marengo’s next-generation, precision T cell engager (TCE) technology. Traditional TCEs targeting ‘c...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.06.2024
IPN
LISTED
EURONEXT
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
News Preview
Monthly information relative to the total number of voting rights and shares composing the share capital...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.06.2024
IPN
LISTED
EURONEXT
Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis
News Preview
PARIS, FRANCE, DD June 2024 Ipsen (Euronext: IPN; ADR: IPSEY) today announced new late-breaking data at the European Association for the Study of the Liver (EASL) Congress demonstrating the enduring efficacy of elafibranor in managing disease progression after 78 weeks of treatment. In the variable double-blind period of the ELATIVE® Phase III tri...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.06.2024
IPN
LISTED
EURONEXT
Ipsen initiates a share buy-back program to cover its free employee share-allocation plan
News Preview
Ipsen initiates a share buy-back program to cover its free employee share-allocation plan and employee share plan...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.05.2024
IPN
LISTED
EURONEXT
Ipsen announces the launch of an employee shareholding plan
News Preview
Ipsen announces the launch of an employee shareholding plan...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.05.2024
IPN
LISTED
EURONEXT
Annual General Meeting of Ipsen S.A. held on 28 May 2024
News Preview
PARIS, FRANCE, 28 May 2024 - The Annual General Meeting of Ipsen S.A. (Euronext: IPN; ADR: IPSEY) was held today at the Salons de l'Hôtel des Arts et Métiers, 9 bis, avenue d'Iéna, 75116 Paris (France), under the chairmanship of Mr. Marc de GARIDEL, Chairman of the Board of Directors, and in the presence of the members of the Board of Directors and...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.05.2024
IPN
LISTED
EURONEXT
Description of the regulatory framework of the share repurchase program proposed by the Board of Directors to be approved at Ipsen S.A.’s Annual General Meeting on 28 May 2024
News Preview
PARIS, FRANCE, 28 May 2024 - In accordance with the provisions of Article L.22-10-62 et seq. of the French Commercial Code, the European Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014, the Delegated Regulation No 2016/1052 of 8 March 2016, and the General Regulation of the French Autorité des Marchés Fin...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.05.2024
IPN
LISTED
EURONEXT
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
News Preview
Monthly information relative to the total number of voting rights and shares composing the share capital...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
